Neoadjuvant Darovasertib in Primary Uveal Melanoma
Trial details
- Registry ID
- NCT07015190
- Drugs studied
- Darovasertib, Primary Local Therapy
TrialRedline tracks 3 clinical trials sponsored by IDEAYA Biosciences: 1 Phase 3, 1 Phase 2 / 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190 | Darovasertib, Primary Local Therapy | Recruiting | 2030-10Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 | Crizotinib, Dacarbazine, IDE196, Ipilimumab and 2 more | Active not recruiting | 2027-01-15Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954 | Darovasertib | Active not recruiting | 2027-04-30Estimated |
Names as written in the registry records.
NCT05907954 · IDEAYA Biosciences
Before: Recruiting. After: Active not recruiting.
NCT05987332 · IDEAYA Biosciences
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. After: Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment..
Before: Recruiting. After: Active not recruiting.